🇺🇸 FDA
Patent

US 8999934

Treatment of astrocytes-tumor cells inhibitors of endothelin receptors

granted A61KA61K31/337A61K31/4188

Quick answer

US patent 8999934 (Treatment of astrocytes-tumor cells inhibitors of endothelin receptors) held by The Board of Regents of the University of Texas System expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/337, A61K31/4188, A61K31/495, A61K31/506